BioCentury | Dec 16, 2013
Strategy

Out in the cold

New excluded drugs lists devised by pharmacy benefits managers are raising the hurdle for reimbursement of drugs the PBMs' pharmacy and therapeutics committees consider to be clinically equivalent to cheaper drugs. Drugs that are not...
BC Week In Review | Sep 23, 2013
Company News

Arbor Pharmaceuticals, Takeda sales and marketing update

Takeda granted Arbor's Arbor Pharmaceuticals Ireland Ltd. subsidiary exclusive rights to commercialize hypertension drugs Edarbi azilsartan medoxomil and Edarbyclor azilsartan medoxomil/chlorthalidone in the U.S. Takeda, which has already launched the products in the U.S., will...
BC Week In Review | Oct 8, 2012
Clinical News

Edarbyclor azilsartan medoxomil/chlorthalidone regulatory update

Takeda said that within the first 8 months of this year, it submitted regulatory applications for azilsartan medoxomil/chlorthalidone in Taiwan, Thailand and Indonesia to treat hypertension. Takeda markets the fixed-dose combination of azilsartan medoxomil, an...
BC Week In Review | Feb 13, 2012
Company News

Takeda sales and marketing update

Takeda launched Edarbyclor azilsartan medoxomil/chlorthalidone in the U.S. to treat hypertension. Edarbyclor is a fixed-dose combination of azilsartan, an angiotensin II type 1 (AT1) receptor blocker, and chlorthalidone, a long-acting thiazide-like diuretic. Azilsartan as a...
BioCentury | Jan 9, 2012
Finance

PDUFAs produce yawns

Stephen Hansen Senior Writer  There are more than twice as many PDUFA dates this year than last - at least 40 vs. 17 - but only a handful of potential approvals are drumming up interest among buysiders....
BC Week In Review | Jan 2, 2012
Clinical News

Edarbyclor azilsartan medoxomil/chlorthalidone regulatory update

FDA approved an NDA from Takeda for Edarbyclor azilsartan/chlorthalidone to treat hypertension. The product is a fixed-dose combination of azilsartan, an angiotensin II type 1 (AT1) receptor blocker, and chlorthalidone, a long-acting thiazide-like diuretic. Azilsartan...
BioCentury | Jan 2, 2012
Finance

Small-fry squashed

Among last year's best-performing large cap biotechs were an acquiree and an acquirer: HCV play Pharmasset Inc. and Valeant Pharmaceuticals International Inc. Other big cap stocks also did well overall, while investors abandoned their small-...
BC Extra | Dec 21, 2011
Company News

FDA approves azilsartan/chlorthalidone for hypertension

FDA approved an NDA from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) for Edarbyclor azilsartan/chlorthalidone to treat hypertension. The product is a fixed-dose combination of azilsartan, an angiotensin II type 1 (AT1) receptor blocker, and chlorthalidone, a...
BC Week In Review | Jun 6, 2011
Clinical News

Azilsartan medoxomil/chlorthalidone: Phase III data

A double-blind, North American Phase III trial in 1,071 patients with moderate to severe hypertension showed that once-daily low- and high-dose combinations of azilsartan medoxomil/chlorthalidone each met the primary endpoint of significantly reducing mean trough...
BC Week In Review | Jun 6, 2011
Clinical News

Azilsartan medoxomil/chlorthalidone: Phase III data

A double-blind, international Phase III trial in 1,085 patients with stage 2 hypertension showed that once-daily low- and high-dose combinations of azilsartan medoxomil/chlorthalidone each met the primary endpoint of significantly reducing mean trough sitting SBP...
Items per page:
1 - 10 of 12